Iobenguane
drugOn this page
Also known as SID11111341SID90341658Metaiodobenzylguanidine(meta-Iodobenzyl)guanidinemeta-iodo-benzylguanidineM-IODOBENZYLGUANIDINE HEMISULFATEmeta-iodobenzyl-guanidinem-lodobenzylguanidine
Summary
Iobenguane (CHEMBL818) is an approved small molecule; indicated across 5 conditions including heart failure and neuroblastoma.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 5 conditions
- Clinical trials: 4
- Chemistry: 275.09 Da · C8H10IN3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL818 |
| Name | Iobenguane |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | no |
| PubChem CID | 60860 |
| Molecular formula | C8H10IN3 |
| Molecular weight | 275.09 |
| InChIKey | PDWUPXJEEYOOTR-UHFFFAOYSA-N |
SMILES: C1=CC(=CC(=C1)I)CN=C(N)N
IUPAC name: 2-[(3-iodophenyl)methyl]guanidine
Also known as: Iobenguane, SID11111341, SID90341658, Metaiodobenzylguanidine, (meta-Iodobenzyl)guanidine, IOBENGUANE, iobenguane, meta-iodo-benzylguanidine, M-IODOBENZYLGUANIDINE HEMISULFATE, meta-iodobenzyl-guanidine, m-lodobenzylguanidine
Parent form; salt/anhydrous children: CHEMBL1255738, CHEMBL1374843, CHEMBL1615777, CHEMBL1615779, CHEMBL3989511, CHEMBL3989523, CHEMBL4584538
Patent coverage: 1,716 distinct patent families (3,759 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 2,266 (60%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Thrombopoietin, Ras-related protein Rab-9A, Cytochrome P450 2D6, Cytochrome P450 1A2, Cytochrome P450 2C19, Hypoxia-inducible factor 1-alpha, Lethal factor.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| THPO | 5.8 | Potency | 1585 | nM | CHEMBL_ACT_4805525 |
| THPO | 5.8 | Potency | 1585 | nM | CHEMBL_ACT_5070276 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| heart failure | 3 | MONDO:0005252 | EFO:0003144 |
| neuroblastoma | 2 | MONDO:0005072 | EFO:0000621 |
| adrenal gland pheochromocytoma | 2 | MONDO:0004974 | EFO:0000239 |
| paraganglioma | 2 | MONDO:0000448 | EFO:1000453 |
| neuroendocrine neoplasm | 0 | MONDO:0019496 | EFO:1001901 |
Clinical trials
Total trials: 4.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 2 |
| PHASE1 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01313936 | PHASE1 | COMPLETED | High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma |
| NCT04510311 | EARLY_PHASE1 | COMPLETED | Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors |
| NCT01370330 | Not specified | AVAILABLE | 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol |
| NCT01822431 | Not specified | UNKNOWN | A Comparison Between Pupillometry, Heart Rate Variability and Metaiodobenzylguanidine Scintigraphy for the Diagnosis of Early Diabetic Autonomic Neuropathy in Type 1 Diabetes |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: heart failure